PRAMEF14: A Potential Drug Target and Biomarker (G729528)

Target Name: PRAMEF14

NCBI ID: G729528

PRAMEF14

Other Name(s): PRAMEF13 | PRA14_HUMAN | PRAME family member 14 | PRAME family member 13

PRAMEF14: A Potential Drug Target and Biomarker

PRAMEF14, also known as PRAMEF13, is a protein that is expressed in various tissues and cells of the body. Its full name is protamine phosphatase and N-methyl-D-aspartate (NMDA) receptor antagonist, and it has been shown to have various physiological functions. PRAMEF14 has also been identified as a potential drug target and biomarker, which could be useful in the development of new treatments for various diseases.

The protein PRAMEF14 is a member of the PRAMEF gene family, which is known for the regulation of various cellular processes, including cell signaling, inflammation, and stress responses. PRAMEF14 is expressed in the brain, heart, liver, and other tissues, and its function is still not fully understood. However, studies have shown that it plays an important role in the regulation of pain perception and neuroprotection.

One of the most promising aspects of PRAMEF14 is its potential as a drug target. PRAMEF14 has been shown to interact with various signaling pathways, including the NMDA receptor pathway. The NMDA receptor is a well-established drug target that is involved in pain perception, neuroprotection, and other physiological processes. By interacting with the NMDA receptor, PRAMEF14 may be able to modulate pain perception and protect against neurodegeneration.

In addition to its potential as a drug target, PRAMEF14 has also been identified as a potential biomarker. The detection and measurement of PRAMEF14 levels may be used as a diagnostic tool for various diseases, including neurodegenerative disorders, pain disorders, and autoimmune diseases.

The identification of PRAMEF14 as a potential drug target and biomarker has important implications for the development of new treatments for various diseases. By modulating pain perception and protecting against neurodegeneration, PRAMEF14 may be a valuable target for the treatment of chronic pain, neurodegenerative disorders, and other conditions.

In conclusion, PRAMEF14 is a protein that has been identified as a potential drug target and biomarker. Its interaction with the NMDA receptor and its expression in various tissues make it an attractive target for the development of new treatments for chronic pain, neurodegenerative disorders, and other conditions. Further research is needed to fully understand its functions and potential as a drug target and biomarker.

Protein Name: PRAME Family Member 14

The "PRAMEF14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets